Drug Profile
Research programme: GPR-119 agonists - iNovacia
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biovitrum
- Developer iNovacia
- Class Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Sweden
- 14 Jan 2010 Biovitrum has combined with Swedish Orphan forming Swedish Orphan Biovitrum
- 22 Jun 2009 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)